

# Marc P Bonaca

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7114055/marc-p-bonaca-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172  
papers

12,908  
citations

47  
h-index

112  
g-index

240  
ext. papers

16,747  
ext. citations

9.5  
avg, IF

6.32  
L-index

#	Paper	IF	Citations
172	Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease.. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2022</b> , 27, 10742484211056115	2.6	0
171	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.. <i>American Heart Journal</i> , <b>2022</b> , 246, 136-136	4.9	1
170	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101806	2.2	1
169	Society for Vascular Surgery Appropriate Use Criteria for Management of Intermittent Claudication.. <i>Journal of Vascular Surgery</i> , <b>2022</b> ,	3.5	3
168	Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD.. <i>Vascular Medicine</i> , <b>2022</b> , 1358863X221085606	3.3	2
167	At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers.. <i>BMC Infectious Diseases</i> , <b>2022</b> , 22, 443	4	0
166	Impact of Polyvascular Disease and Diabetes on Limb and Cardiovascular Risk in Peripheral Artery Disease.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1781-1783	15.1	1
165	Call for Formalized Pathways in Vascular Medicine Training. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 2129-2139	15.1	1
164	Challenges of Long-term Dual Antiplatelet Therapy Use Following Acute Coronary Syndromes: Patient Selection for Long-term DAPT After ACS.. <i>American Heart Journal</i> , <b>2021</b> , 246, 44-44	4.9	0
163	Studying the coagulopathy of COVID-19. <i>Lancet, The</i> , <b>2021</b> ,	40	4
162	Novel views on finding an old foe: non-contrast computed tomography in the diagnosis of acute aortic syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2021</b> , 10, 976-977	4.3	
161	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , <b>2021</b> , 144, 1831-1841	16.7	4
160	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021412	6	0
159	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1768-1778	15.1	3
158	Acute Aortic Syndromes. <i>Cardiology Clinics</i> , <b>2021</b> , 39, 495-503	2.5	2
157	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2P-TIMI 50. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e018673	6	3
156	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , <b>2021</b> , 42, 4638-4651	9.5	21

155	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , <b>2021</b> , 235, 12-23	4.9	14
154	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 3016-3027	15.1	4
153	Contemporary Medical Management of Peripheral Artery Disease. <i>Circulation Research</i> , <b>2021</b> , 128, 1868-1884	15.8	10
152	Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2867-2869	15.1	3
151	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 317-326	15.1	6
150	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , <b>2021</b> , 143, 470-478	16.7	13
149	Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. <i>Heart International</i> , <b>2021</b> , 15, 14	0.3	1
148	Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. <i>Journal of Medical Economics</i> , <b>2021</b> , 24, 402-409	2.4	0
147	Recombinant human Lecithin-Cholesterol acyltransferase in patients with atherosclerosis: Phase 2a primary results and phase 2b design. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	6.4	7
146	Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease. <i>JACC Basic To Translational Science</i> , <b>2021</b> , 6, 174-188	8.7	7
145	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , <b>2021</b> , 143, 685-695	16.7	3
144	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , <b>2021</b> , 14, e003006	5.2	1
143	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , <b>2021</b> , 319, 51-61	3.1	12
142	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017008	6	6
141	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2021</b> , 14, e009871	6	
140	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , <b>2021</b> , 144, 1104-1116	16.7	2
139	Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 1333-1343	3.3	1
138	Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 757-759	15.1	1

137	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 4040-4048	8.5	3
136	Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. <i>Annals of Vascular Surgery</i> , <b>2021</b> , 75, 217-226	1.7	1
135	Supervised Exercise Therapy for Symptomatic Peripheral Artery Disease Among Medicare Beneficiaries Between 2017 and 2018: Participation Rates and Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e007953	5.8	11
134	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020446	6	1
133	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	5
132	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. <i>Circulation</i> , <b>2020</b> , 142, 2219-2230	16.7	17
131	Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e015331	6	16
130	Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e015785	6	2
129	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1095-1106	15.1	12
128	Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1994-2004	59.2	248
127	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , <b>2020</b> , 141, 1600-1607	16.7	32
126	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. <i>Circulation</i> , <b>2020</b> , 141, 1227-1234	16.7	97
125	American Heart Association Vascular Disease Strategically Focused Research Network. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2020</b> , 40, e47-e54	9.4	
124	Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. <i>Current Cardiology Reports</i> , <b>2020</b> , 22, 13	4.2	1
123	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1357-1368	6.7	13
122	Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , <b>2020</b> , 142,	16.7	1
121	Abstract 17116: Incidence and Costs of Major Atherothrombotic Vascular Events Among Patients With Peripheral Artery Disease After Revascularization. <i>Circulation</i> , <b>2020</b> , 142,	16.7	1
120	Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2P-TIMI 50 trial. <i>Vascular Medicine</i> , <b>2020</b> , 25, 124-132	3.3	15

119	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , <b>2020</b> , 41, 1625-1632	9.5	19
118	Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. <i>Expert Review of Cardiovascular Therapy</i> , <b>2020</b> , 18, 881-889	2.5	1
117	Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e009584	6	5
116	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1255-1262	16.2	12
115	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 1012-1014	5	3
114	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , <b>2020</b> , 142, 734-747	16.7	16
113	Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries. <i>Archives of Cardiovascular Diseases</i> , <b>2019</b> , 112, 459-468	2.7	6
112	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2019</b> , 5, 200-206	6.4	17
111	Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2 <sup>MP</sup> -TIMI 50 trial. <i>Vascular Medicine</i> , <b>2019</b> , 24, 159-161	3.3	3
110	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , <b>2019</b> , 139, 2516-2527	16.7	142
109	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 2528-2536	16.7	283
108	Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTEMI-ACS. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2019</b> , 57, 1084-1092	5.9	7
107	Microvascular Disease, Peripheral Artery Disease, and Amputation. <i>Circulation</i> , <b>2019</b> , 140, 449-458	16.7	53
106	Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. <i>Circulation</i> , <b>2019</b> , 140, 80-91	16.7	153
105	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 899-911	18.1	61
104	Descending Aortic Dissection, Penetrating Aortic Ulcer, and Intramural Hematoma (Acute and Chronic) Including Kommerell's Diverticulum <b>2019</b> , 149-160		2
103	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 2022-2031	16.7	345
102	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 347-357	59.2	2455

101	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet, The</i> , <b>2019</b> , 393, 31-39	40	1300
100	Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 413-421	3.8	11
99	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , <b>2019</b> , 139, 366-375	16.7	21
98	Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 411-419	3.9	6
97	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 353-360	5.1	6
96	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 145-152	3	16
95	Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2 <sup>MP</sup> -TIMI 50 Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2019</b> , 2048872619883354	4.3	2
94	Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. <i>Clinical Cardiology</i> , <b>2019</b> , 42, 227-234	3.3	8
93	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 489-496	15.1	41
92	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <i>American Heart Journal</i> , <b>2018</b> , 199, 83-91	4.9	71
91	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , <b>2018</b> , 200, 83-89	4.9	89
90	DECLARE-TIMI 58: Participants' baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1107-1108	7.1	1108
89	Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 108	15.1	1
88	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. <i>Atherosclerosis</i> , <b>2018</b> , 272, 80-86	3.1	19
87	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , <b>2018</b> , 137, 684-692	16.7	10
86	International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	16
85	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1107-1117	59.2	143
84	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). <i>Circulation</i> , <b>2018</b> , 137, 338-350	16.7	348

83	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1579-1589	21.7	395
82	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009260	6	7
81	Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)". <i>Circulation</i> , <b>2018</b> , 138, 222-223	16.7	9
80	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 392, 2269-2279	4 <sup>0</sup>	4 <sup>6</sup>
79	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2018</b> , 6, 934-943	18.1	58
78	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2 <sup>°</sup> P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2017</b> , 6, 164-172	4.3	7
77	Utility of multimodality imaging in myopericarditis with aortitis. <i>Journal of Nuclear Cardiology</i> , <b>2017</b> , 24, 1103-1106	2.1	1
76	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 962-969	6.7	19
75	Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 712-724	5	34
74	Potent P2Y Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1549-1559	15.1	36
73	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 <sup>°</sup> P - TIMI 50 Trial. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 307-315	5.5	16
72	Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction. <i>Interventional Cardiology Clinics</i> , <b>2017</b> , 6, 119-129	1.4	2
71	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1368-1375	15.1	50
70	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 527-538	15.1	17
69	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 940-947	7	20
68	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , <b>2016</b> , 37, 390-9	9.5	232
67	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. <i>European Heart Journal</i> , <b>2016</b> , 37, 400-8	9.5	54
66	Antithrombotic Therapy in Patients With Peripheral Artery Disease. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 803-804	16.2	

65	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). <i>Circulation</i> , <b>2016</b> , 134, 861-71	16.7	34
64	Recurrent Aortic Dissection: Observations From the International Registry of Aortic Dissection. <i>Circulation</i> , <b>2016</b> , 134, 1013-1024	16.7	42
63	Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 627-8	16.2	7
62	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , <b>2016</b> , 134, 304-13	16.7	102
61	Randomized Controlled Trial of Social Media: Effect of Increased Intensity of the Intervention. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	34
60	Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2P-TIMI 50 Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 2157-2164	5	26
59	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 425-32	16.2	70
58	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2P-TIMI 50). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1055-8	3	4
57	Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2P-TIMI 50). <i>Circulation</i> , <b>2016</b> , 133, 997-1005	16.7	120
56	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1145-1154	15.1	82
55	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , <b>2016</b> , 37, 1133-42	9.5	103
54	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 322-323	15.1	11
53	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2719-2728	15.1	225
52	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2732-2740	15.1	141
51	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1591-9	27.4	144
50	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P)-TIMI 50. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	12
49	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 431-40	4.3	13
48	Long-term use of ticagrelor in patients with prior myocardial infarction. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1791-800	59.2	1193



47	Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. <i>Circulation</i> , <b>2015</b> , 131, 1047-53	16.7	59
46	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1274-5	59.2	48
45	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2 <sup>®</sup> P-TIMI 50. <i>Circulation</i> , <b>2015</b> , 132, 1871-9	16.7	30
44	Pharmacological treatment and current management of peripheral artery disease. <i>Circulation Research</i> , <b>2015</b> , 116, 1579-98	15.7	66
43	Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. <i>Clinical Cardiology</i> , <b>2015</b> , 38, 230-5	3.3	14
42	TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, B36	15.1	7
41	Efficacy and safety of vorapaxar as approved for clinical use in the United States. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e001505	6	55
40	Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). <i>Clinical Cardiology</i> , <b>2014</b> , 37, 1111-5	15.1	64
39	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , <b>2014</b> , 167, 437-444.e5	4.9	74
38	Diagnostic performance of copeptin in patients with acute nontraumatic chest pain: BWH-TIMI ED chest pain study. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 227-32	3.3	8
37	Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 350-6	3.3	10
36	Diagnosis and management of acute aortic syndromes: dissection, intramural hematoma, and penetrating aortic ulcer. <i>Current Cardiology Reports</i> , <b>2014</b> , 16, 536	4.2	32
35	Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. <i>Clinical Chemistry</i> , <b>2014</b> , 60, 158-64	5.5	59
34	Primary Stroke Prevention: Medical Therapy Versus Revascularization. <i>Interventional Cardiology Clinics</i> , <b>2014</b> , 3, 1-11	1.4	
33	Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2 <sup>®</sup> P-TIMI 50 trial. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2309-17	15.1	37
32	Patterns of long-term thienopyridine therapy and outcomes in patients with acute coronary syndrome treated with coronary stenting: Observations from the TIMI-38 Coronary Stent Registry. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 293-9	3.3	3
31	New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 <sup>®</sup> P-TIMI 50 trial. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2318-26	15.1	29
30	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1006-15	27.4	285

29	Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 36, 361-7	5.1	16
28	Acute dissection of the descending aorta: a case report and review of the literature. <i>Cardiology and Therapy</i> , <b>2013</b> , 2, 199-213	2.8	7
27	Management of asymptomatic carotid artery stenosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2013</b> , 15, 252-63	2.1	1
26	Efficacy and safety of vorapaxar in patients with prior ischemic stroke. <i>Stroke</i> , <b>2013</b> , 44, 691-8	6.7	80
25	Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2013</b> , 2, 195-202	4.3	24
24	Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. <i>Circulation</i> , <b>2013</b> , 127, 1522-9, 1529e1-6	16.7	208
23	Ticagrelor for acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 1473-84	2.5	0
22	American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial	16.7	129
21	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2{degrees}P-TIMI 50 trial. <i>Lancet, The</i> , <b>2012</b> , 380, 1317-24	4 <sup>0</sup>	177
20	Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 332-8	15.1	46
19	Vorapaxar in the secondary prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1404-13	59.2	694
18	Elevated concentration of placental growth factor (PLGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 222-8	5.1	9
17	Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 229-34	5.1	16
16	Response to Letter Regarding Articles, Long-Term Cardiovascular Mortality After Procedure-Related or Spontaneous Myocardial Infarction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Collaborative Analysis of Individual Patient Data From the PRISON, ICTUS, and RITA-3 Trials (FIR) and American College of Cardiology/American Heart	16.7	3
15	Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. <i>Heart</i> , <b>2012</b> , 98, 786-91	5.1	29
14	Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. <i>Clinical Chemistry</i> , <b>2012</b> , 58, 257-66	5.5	115
13	Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 203-10	9.4	103
12	Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. <i>Heart</i> , <b>2011</b> , 97, 1782-7	5.1	43

11	Left ventricular thrombosis refractory to medical therapy. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, e37	15.1	
10	Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2118-24	15.1	105
9	Antithrombotics in acute coronary syndromes: updates from the past year. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2010</b> , 12, 84-99	2.1	1
8	Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. <i>Circulation</i> , <b>2009</b> , 119, 2758-64	16.7	137
7	SCH 530348: a novel oral thrombin receptor antagonist. <i>Future Cardiology</i> , <b>2009</b> , 5, 435-42	1.3	13
6	Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. <i>Journal of Emergency Medicine</i> , <b>2009</b> , 36, 162-70	1.5	1
5	Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. <i>American Heart Journal</i> , <b>2009</b> , 158, 335-341.e3	4.9	157
4	Antithrombotics in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 969-84	15.1	44
3	Subclavian stenosis causing angina after coronary artery bypass grafting. <i>Medical Journal of Australia</i> , <b>2009</b> , 190, 331-2	4	2
2	Defining a role for novel biomarkers in acute coronary syndromes. <i>Clinical Chemistry</i> , <b>2008</b> , 54, 1424-31	5.5	20
1	Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 344-8	3	8